drugset / Trial / NCT03277352
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
Timeline
- Start
- 2017-11-21
- Primary completion
- 2020-07-01
- Completion
- 2020-07-01
Outcome
Outcome not reported
Stopped: “The study was terminated due to emergent data from another study and unrelated to safety.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RAGIFILIMAB | Monoclonal antibody | — | Intravenous |
| Background | Epacadostat | Small molecule | — | Oral |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |